
CORRIGENDUM TO CIRCULAR DATED 11 APRIL 2019

Pharmesis International Ltd. ("**Company**") together with its subsidiaries, collectively the "**Group**") refers to the Circular dated 11 April 2019 and wishes to make a revision on the Circular as set forth below.

Please refer to **DEFINITIONS** on page 2 of the circular, the information should be read as follows:

- "**Chengdu Kinna Investment**" : 成都国嘉投资股份有限公司 (Chengdu Kinna Investment Co., Ltd.)
- "**Chengdu Kinna Pharma**" : 成都国嘉联合制药有限公司 (Chengdu Kinna Pharmaceutical Co., Ltd)

Please refer to **DEFINITIONS** on page 4 of the circular, the information should be read as follows:

- "**Sichuan Longlife**" : 四川古藓肝苏药业有限公司 (Sichuan Longlife Pharmaceutical Co., Ltd)

Please refer to the **INTRODUCTION** on page 5 of the circular, the information should be read as follows:

On 31 December 2018, the Company announced that Chengdu Kinna Pharma, a wholly-owned subsidiary of the Company, had on 31 December 2018 entered into the SPA to acquire 30% of the equity interest (the "**Equity Interest**") in the registered capital of 四川古藓肝苏药业有限公司 (Sichuan Longlife Pharmaceutical Co., Ltd) ("**Sichuan Longlife**") from 成都国嘉投资股份有限公司 (Chengdu Kinna Investment Co., Ltd.) ("**Chengdu Kinna Investment**") (the "**Announcement**").

Please refer to the **NOTICE OF EXTRAORDINARY GENERAL MEETING** on page 122 of the circular, the information should be read as follows:

- (a) approval be and is hereby given for the purpose of Chapter 10 of the Listing Manual for the proposed acquisition by 成都国嘉联合制药有限公司 (Chengdu Kinna Pharmaceutical Co., Ltd) ("**Chengdu Kinna Pharma**"), a wholly-owned subsidiary of the Company, of 30% of the equity interest ("**Equity Interest**") in the registered capital of 四川古藓肝苏药业有限公司 (Sichuan Longlife Pharmaceutical Co., Ltd) from 成都国嘉投资股份有限公司 (Chengdu Kinna Investment Co., Ltd.) ("**Chengdu Kinna Investment**"), for an aggregate purchase consideration of RMB15,700,000, on the terms and subject to the conditions of the sale and purchase agreement entered into between Chengdu Kinna Pharma and Chengdu Kinna Investment;